The OpenGame Course curriculum and content

The course on open education proposed here comprises 8 modules based on 8 competences. For each competence we have defined learning outcomes. The modules are built around the practices identified and described in IO1. In each module 3 practices are used to engage the trainees. The practices themselves are transformed into learning activities, allowing the trainees to actively interact with the learning activities.OpenGame Project -Promoting Open Education through Gamification, Ref: 2019-1-ES01-KA203-065815info:eu-repo/semantics/publishedVersio

Biomass-modulated fire dynamics during the last glacial-interglacial transition at the central pyrenees (Spain)

Understanding long-term fire ecology is essential for current day interpretation of ecosystem fire responses. However palaeoecology of fire is still poorly understood, especially at high-altitude mountain environments, despite the fact that these are fire-sensitive ecosystems and their resilience might be affected by changing fire regimes. We reconstruct wildfire occurrence since the Lateglacial (14.7. cal. ka BP) to the Mid-Holocene (6. cal. ka BP) and investigate the climate-fuel-fire relationships in a sedimentary sequence located at the treeline in the Central Spanish Pyrenees. Pollen, macro- and micro-charcoal were analysed for the identification of fire events (FE) in order to detect vegetation post-fire response and to define biomass-fire interactions. mean fire intervals (mfi) reduced since the Lateglacial, peaking at 9-7.7. cal. ka BP while from 7.7 to 6. cal. ka BP no fire is recorded. We hypothesise that Early Holocene maximum summer insolation, as climate forcing, and mesophyte forest expansion, as a fuel-creating factor, were responsible for accelerating fire occurrence in the Central Pyrenees treeline. We also found that fire had long-lasting negative effects on most of the treeline plant communities and that forest contraction from 7.7. cal. ka BP is likely linked to the ecosystem's threshold response to high fire frequencies.This research has been funded by the projects DINAMO (CGL2009-07992) (funding EGPF — grant ref. BES-2010-038593 and MSC), DINAMO2 (CGL2012-33063), ARAFIRE (2012 GA LC 064), GRACCIE-CONSOLIDER (CSD2007-00067). GGR was funded by the Juan de la Cierva Program (grant ref. JCI2009-04345) and JAE-Doc CSIC Program, LLM was supported by a postdoctoral MINT fellowship funded by the Institute for the Environment (Brunel University), AMC is a Ramón y Cajal fellow (ref: RYC-2008-02431), APS holds a grant funded by the Aragon Government (ref. 17030G/5423/480072/14003) and JAE holds a grant funded by the Basque Country Government (BFI-2010-5)

O currículo e o conteúdo do curso OpenGame

O curso sobre educação aberta aqui proposto é composto por 8 módulos baseados em 8 competências. Para cada competência, definimos resultados de aprendizagem. Os módulos são construídos em torno das práticas identificadas e descritas em IO1. Em cada módulo são utilizadas 3 práticas para envolver os formandos. As próprias práticas são transformadas em atividades de aprendizagem, permitindo aos formandos interagir ativamente com ativamente com as atividades de aprendizagem..Projeto OpenGame - Promover a Educação Aberta através da Gamificação - Ref: 2019-1-ES01-KA203-065815info:eu-repo/semantics/publishedVersio

Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection

Introduction and Objectives: Viral infections have been described to increase the risk of decompensation in patients with cirrhosis. We aimed to determine the effect of SARS-CoV-2 infection on outcome of hospitalized patients with cirrhosis and to compare the performance of different prognostic models for predicting mortality. Patients: We performed a prospective cohort study including 2211 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through October 1, 2020 in 38 Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters of patients with and without cirrhosis. All patients were followed until discharge or death. We evaluated the prognostic performance of different scoring systems to predict mortality in patients with cirrhosis using ROC curves. Results: Overall, 4.6% (CI 3.7–5.6) subjects had cirrhosis (n = 96). Baseline Child-Turcotte-Pugh (CTP) class was assessed: CTP-A (23%), CTP-B (45%) and CTP-C (32%); median MELD-Na score was 19 (IQR 14−25). Mortality was 47% in patients with cirrhosis and 16% in patients without cirrhosis (P 30. The areas under the ROC curves for performance evaluation in predicting 28-days mortality for Chronic Liver Failure Consortium (CLIF-C), North American Consortium for the Study of End-Stage Liver Disease (NACSELD), CTP score and MELD-Na were 0.85, 0.75, 0.69, 0.67; respectively (P < .0001). Conclusions: SARS-CoV-2 infection is associated with elevated mortality in patients with cirrhosis. CLIFC had better performance in predicting mortality than NACSELD, CTP and MELD-Na in patients with cirrhosis and SARS-CoV-2 infection. Clinicaltrials.gov:NCT04358380.Fil: Mendizabal, Manuel. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; ArgentinaFil: Ridruejo, Ezequiel. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Centro de Educación Médica e Investigaciones Clínicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Piñero, Federico. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; ArgentinaFil: Anders, Margarita. Hospital Alemán; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; ArgentinaFil: Padilla, Martín Jesus. Hospital Nacional Guillermo Almenara Irigoyen; PerúFil: Toro, Luis G.. Fundación de Medellín y Rionegro; ColombiaFil: Torre, Aldo. Instituto Nacional de Ciencias Médicas y Nutrición; MéxicoFil: Montes, Pedro. Hospital Nacional Daniel A. Carrión; ArgentinaFil: Urzúa, Alvaro. Universidad de Chile; ChileFil: Gonzalez Ballerga, Esteban. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Silveyra, María Dolores. Sanatorio Anchorena; ArgentinaFil: Michelato, Douglas. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; BrasilFil: Díaz, Javier. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: Peralta, Mirta. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; ArgentinaFil: Pages, Josefina. Universidad Austral; Argentina. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; ArgentinaFil: García, Sandro Ruiz. Hospital de Víctor Lazarte Echegaray; PerúFil: Gutierrez Lozano, Isabel. Centro Médico ABC; MéxicoFil: Macias, Yuridia. IMSS Hospital General Regional No. 1 “Dr. Carlos Mc Gregor Sánchez”; MéxicoFil: Cocozzella, Daniel. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Hospital Italiano de La Plata; ArgentinaFil: Chavez Tapia, Norberto. Medica Sur Clinic & Foundation; MéxicoFil: Tagle, Martín. Clínica Anglo-Americana; PerúFil: Dominguez, Alejandra. Hospital Padre Hurtado; ChileFil: Varón, Adriana. Red Latinoamericana de Concientización y Educación en Investigación del Hígado; Argentina. Fundación Cardio Infantil; ColombiaFil: Vera Pozo, Emilia. Hospital Regional Dr. Teodoro Maldonado Carbo del IESS; EcuadorFil: Higuera de la Tijera, Fátima. Hospital General de México “Dr. Eduardo Liceaga”; MéxicoFil: Bustios, Carla. Fundación Cardio Infantil; ColombiaFil: Conte, Damián. Hospital Privado de Córdoba; ArgentinaFil: Escajadillo, Nataly. Universidad Austral; ArgentinaFil: Rubinstein, Fernando Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Hospital Especializado en Enfermedades Infecciosas Instituto Couto Maia; BrasilFil: Tenorio, Laura. Hospital Nacional Edgardo Rebagliati Martins; Per

Impact of vaccination against Haemophilus influenzae type b with and without a booster dose on meningitis in four South American countries

Fil: García, Salvador. Pan American Health Organization, Washington DC; Estados Unidos.Fil: Lagos, Rosanna. Centro para Vacunas en Desarrollo (CVD-Chile), Santiago; Chile.Fil: Muñoz, Alma. Centro para Vacunas en Desarrollo (CVD-Chile), Santiago; Chile.Fil: Picón, Teresa. National Immunization Program and Department of Epidemiologic Surveillance, Ministry of Health, Montevideo; Uruguay.Fil: Rosa, Raquel. National Immunization Program and Department of Epidemiologic Surveillance, Ministry of Health, Montevideo; Uruguay.Fil: Alfonso, Adriana. National Immunization Program and Department of Epidemiologic Surveillance, Ministry of Health, Montevideo; Uruguay.Fil: Abriata, Graciela. Instituto Nacional del Cáncer, Ministerio de Salud de la Nación, Buenos Aires; Argentina.Fil: Gentile, Angela. Hospital de Niños Ricardo Gutierrez, Epidemiología, Buenos Aires; Argentina.Fil: Romanin, Viviana. Hospital de Niños Ricardo Gutierrez, Epidemiología, Buenos Aires; Argentina.Fil: Regueira, Mabel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Chiavetta, Laura. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Agudelo, Clara Inés. Instituto Nacional de Salud, Bogotá; Colombia.Fil: Castañeda, Elizabeth. Instituto Nacional de Salud, Bogotá; Colombia.Fil: De la Hoz, Fernando. Facultad de Medicina, Departamento de Salud Pública, Universidad Nacional de Colombia, Bogotá; Colombia.Fil: Higuera, Ana Betty. Secretaria de Salud de Bogotá, Bogotá; Colombia.Fil: Arce, Patricia. Secretaria de Salud de Bogotá, Bogotá; Colombia.Fil: Cohen, Adam L.. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA; Estados Unidos.Fil: Verani, Jennifer. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA; Estados Unidos.Fil: Zuber, Patrick. Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva; Suiza.Fil: Gabastou, Jean-Marc. Pan American Health Organization, Washington DC; Estados Unidos.Fil: Pastor, Desiree. Pan American Health Organization, Washington DC; Estados Unidos.Fil: Flannery, Brendan. Pan American Health Organization, Washington DC; Estados Unidos.Fil: Andrus, Jon. Pan American Health Organization, Washington DC; Estados Unidos.To inform World Health Organization recommendations regarding use of Haemophilus influenzae type b (Hib) vaccines in national immunization programs, a multi-country evaluation of trends in Hib meningitis incidence and prevalence of nasopharyngeal Hib carriage was conducted in four South American countries using either a primary, three-dose immunization schedule without a booster dose or with a booster dose in the second year of life. Surveillance data suggest that high coverage of Hib conjugate vaccine sustained low incidence of Hib meningitis and low prevalence of Hib carriage whether or not a booster dose was used

Impact of vaccination against Haemophilus influenzae type b with and without a booster dose on meningitis in four South American countries

Fil: García, Salvador. Pan American Health Organization, Washington DC; Estados Unidos.Fil: Lagos, Rosanna. Centro para Vacunas en Desarrollo (CVD-Chile), Santiago; Chile.Fil: Muñoz, Alma. Centro para Vacunas en Desarrollo (CVD-Chile), Santiago; Chile.Fil: Picón, Teresa. National Immunization Program and Department of Epidemiologic Surveillance, Ministry of Health, Montevideo; Uruguay.Fil: Rosa, Raquel. National Immunization Program and Department of Epidemiologic Surveillance, Ministry of Health, Montevideo; Uruguay.Fil: Alfonso, Adriana. National Immunization Program and Department of Epidemiologic Surveillance, Ministry of Health, Montevideo; Uruguay.Fil: Abriata, Graciela. Instituto Nacional del Cáncer, Ministerio de Salud de la Nación, Buenos Aires; Argentina.Fil: Gentile, Angela. Hospital de Niños Ricardo Gutierrez, Epidemiología, Buenos Aires; Argentina.Fil: Romanin, Viviana. Hospital de Niños Ricardo Gutierrez, Epidemiología, Buenos Aires; Argentina.Fil: Regueira, Mabel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Chiavetta, Laura. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Agudelo, Clara Inés. Instituto Nacional de Salud, Bogotá; Colombia.Fil: Castañeda, Elizabeth. Instituto Nacional de Salud, Bogotá; Colombia.Fil: De la Hoz, Fernando. Facultad de Medicina, Departamento de Salud Pública, Universidad Nacional de Colombia, Bogotá; Colombia.Fil: Higuera, Ana Betty. Secretaria de Salud de Bogotá, Bogotá; Colombia.Fil: Arce, Patricia. Secretaria de Salud de Bogotá, Bogotá; Colombia.Fil: Cohen, Adam L.. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA; Estados Unidos.Fil: Verani, Jennifer. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA; Estados Unidos.Fil: Zuber, Patrick. Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva; Suiza.Fil: Gabastou, Jean-Marc. Pan American Health Organization, Washington DC; Estados Unidos.Fil: Pastor, Desiree. Pan American Health Organization, Washington DC; Estados Unidos.Fil: Flannery, Brendan. Pan American Health Organization, Washington DC; Estados Unidos.Fil: Andrus, Jon. Pan American Health Organization, Washington DC; Estados Unidos.To inform World Health Organization recommendations regarding use of Haemophilus influenzae type b (Hib) vaccines in national immunization programs, a multi-country evaluation of trends in Hib meningitis incidence and prevalence of nasopharyngeal Hib carriage was conducted in four South American countries using either a primary, three-dose immunization schedule without a booster dose or with a booster dose in the second year of life. Surveillance data suggest that high coverage of Hib conjugate vaccine sustained low incidence of Hib meningitis and low prevalence of Hib carriage whether or not a booster dose was used

Formación de los tutores de las prácticas externas como herramienta eficaz en la mejora del aprendizaje del estudiante y su inserción laboral

El objetivo del proyecto es mejorar la calidad de la tutorización de las prácticas externas y fomentar las buenas prácticas que garanticen el proceso de enseñanza-aprendizaje. Están implicados tutores académicos, externos, instituciones y estudiante

The Mexican consensus on alcoholic hepatitis

Alcoholic hepatitis is a frequent condition in the Mexican population. It is characterized by acute-on-chronic liver failure, important systemic inflammatory response, and multiple organ failure. The severe variant of the disease implies elevated mortality. Therefore, the Asociación Mexicana de Gastroenterología and the Asociación Mexicana de Hepatología brought together a multidisciplinary team of health professionals to formulate the first Mexican consensus on alcoholic hepatitis, carried out utilizing the Delphi method and resultingin 37 recommendations. Alcohol-related liver disease covers a broad spectrum of patholo-gies that includes steatosis, steatohepatitis, different grades of fibrosis, and cirrhosis and itscomplications. Severe alcoholic hepatitis is defined by a modified Maddrey’s discriminant func-tion score ≥ 32 or by a Model for End-Stage Liver Disease (MELD) score equal to or above 21.There is currently no specific biomarker for its diagnosis. Leukocytosis with neutrophilia, hyper-bilirubinemia (>3 mg/dl), AST > 50 U/l ( 1.5-2 can guide thediagnosis. Abstinence from alcohol, together with nutritional support, is the cornerstone oftreatment. Steroids are indicated for severe disease and have been effective in reducing the28-day mortality rate. At present, liver transplantation is the only life-saving option for patientsthat are nonresponders to steroids. Certain drugs, such as N-acetylcysteine, granulocyte-colonystimulating factor, and metadoxine, can be adjuvant therapies with a positive impact on patientsurvival

Consenso Mexicano para el Tratamiento de la Hepatitis C

El objetivo del Consenso Mexicano para el Tratamiento de la Hepatitis C fue el de desarrollar un documento como guía en la práctica clínica con aplicabilidad en México. Se tomó en cuenta la opinión de expertos en el tema con especialidad en: gastroenterología, infectología y hepatología. Se realizó una revisión de la bibliografía en MEDLINE, EMBASE y CENTRAL mediante palabras claves referentes al tratamiento de la hepatitis C. Posteriormente se evaluó la calidad de la evidencia mediante el sistema GRADE y se redactaron enunciados, los cuales fueron sometidos a voto mediante un sistema modificado Delphi, y posteriormente se realizó revisión y corrección de los enunciados por un panel de 34 votantes. Finalmente se clasificó el nivel de acuerdo para cada oración. Esta guía busca dar recomendaciones con énfasis en los nuevos antivirales de acción directa y de esta manera facilitar su uso en la práctica clínica. Cada caso debe ser individualizado según sus comorbilidades y el manejo de estos pacientes siempre debe ser multidisciplinario. Abstract The aim of the Mexican Consensus on the Treatment of Hepatitis C was to develop clinical practice guidelines applicable to Mexico. The expert opinion of specialists in the following areas was taken into account: gastroenterology, infectious diseases, and hepatology. A search of the medical literature was carried out on the MEDLINE, EMBASE, and CENTRAL databases through keywords related to hepatitis C treatment. The quality of evidence was subsequently evaluated using the GRADE system and the consensus statements were formulated. The statements were then voted upon, using the modified Delphi system, and reviewed and corrected by a panel of 34 voting participants. Finally, the level of agreement was classified for each statement. The present guidelines provide recommendations with an emphasis on the new direct-acting antivirals, to facilitate their use in clinical practice. Each case must be individualized according to the comorbidities involved and patient management must always be multidisciplinary

Time Following a Gluten-Free Diet, Ultra-Processed Food Consumption and Quality of Life in Children with Celiac Disease

Maintaining a strict gluten-free diet (GFD) may affect the quality of life of children with celiac disease (CD) and promote a less healthy diet by substituting gluten-containing foods with ultra-processed foods. We aimed to assess the influences of the GFD and ultra-processed food consumption on parents&rsquo; perception of the quality of life of children with CD. Fifty-eight children (mean age 8.6 &plusmn; 4.1 years) were included. The participants were divided into groups based on the time following a GFD: &lt;6 months (n = 18) versus &ge;12 months (n = 37). Their dietary consumption was assessed through a three-day food record. The 20-item Celiac Disease Quality Of Life survey (CD-QOL), which contains four subscales (limitations, dysphoria, health concerns, and inadequate treatment) was used to assess the quality of life. The children who followed a GFD for &ge;12 months presented poorer scores in the limitations subscale than those who followed a GFD for &lt;6 months (p = 0.010). The mean % of the energy intake from ultra-processed foods was 47.3 &plusmn; 13.5. Children with CD consuming more than 50% of their total energy from ultra-processed foods showed poorer scores for the limitation and inadequate treatment (both, p = 0.019) subscales than their counterparts. According to parents&rsquo; perceptions, those children who consumed more than 50% of their energy through ultra-processed foods had more limitations, and their treatment was perceived as less effective